breast cancer

News

NICE’s track record in cancer drugs: the impact of the CDF and the role of interim funding

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxte...

AstraZeneca and Daiichi Sankyo have revealed new data from datopotamab deruxtecan in triple negative breast cancer (TNBC) – and although it’s from a small patient group results look impress

News

Tecentriq can stay as therapy for triple-negative breast can...

Roche’s Tecentriq can stay on the US market as a therapy for triple negative breast cancer, advisers to the FDA have said as part of a review of several quickly-approved cancer drugs.

News

Enhertu cleared for NHS use via Cancer Drugs Fund

NICE has recommended the use of AstraZeneca and Daiichi Sankyo's Enhertu in draft guidance, the first time the drug has been commissioned in any European country.

News

Gilead scores US approval for breast cancer drug that wowed ...

Gilead’s $21 billion purchase of Immunomedics and its potential blockbuster Trodelvy continues to pay off, as the drug has now been approved by the FDA for triple-negative breast cancer.

News

NICE okays regular NHS funding for Novartis' breast cancer d...

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients.

News

Filing beckons as Lynparza hits the mark in adjuvant breast ...

AstraZeneca’s PARP inhibitor Lynparza has shown a clinical benefit when given as an adjuvant for early breast cancer, according to the data monitoring body for the phase 3 OlympiA trial.

AZ/Daiichi unveil data from TNBC hopeful datopotamab deruxte...

Tecentriq can stay as therapy for triple-negative breast can...

Enhertu cleared for NHS use via Cancer Drugs Fund

Gilead scores US approval for breast cancer drug that wowed ...

NICE okays regular NHS funding for Novartis' breast cancer d...

Filing beckons as Lynparza hits the mark in adjuvant breast ...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

breast cancer

Editor's Picks